Illicit drugs: What dermatologists need to know.

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

Anesthetic management of the illicit-substance-using patient.

PURPOSE OF REVIEW During the last few years, drug abuse has risen to the point that almost 20 million Americans are current abusers of illicit substances. These patients present to us as anesthesiologists in a variety of circumstances: in obstetrics for labor and emergencies, in trauma for emergency surgeries or life-saving (resuscitative) situations and in everyday elective surgeries. Therefor...

Price and purity analysis for illicit drug: data and conceptual issues.

Data on illicit drug purity and prices are invaluable but challenging. Academic purists argue they are unsuitable for economic analysis [Manski, C.F., Pepper, J.V., Petrie, C.V., 2001. Informing America's Policy on Illegal Drugs: What We Don't Know Keeps Hurting Us. National Academy Press, Washington, DC], but in practice they are used frequently [ONDCP, 2001a. What America's Users Spend on Ill...

Coronavirus disease 2019 (COVID-19): What we need to know (In Press)

Illicit drugs in Central Asia: what we know, what we don’t know, and what we need to know.

In 2013, two special issues with focus on health and drugs in entral Asia were published in Drug and Alcohol Dependence and entral Asian Survey journals (El-Bassel, Strathdee, & El Sadr, 2013; atypov, 2013, 2014). In this third special issue published by the nternational Journal of Drug Policy, the authors of ten research apers and commentaries seek to provide additional knowledge n a range of ...